Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Gian Poalo FadiniEnrico LongatoMario Luca MorieriEnzo BonoraAgostino ConsoliBruno FattorMauro RigatoFederica TurchiStephano Del PratoAngelo AvogaroAnna Solininull nullPublished in: Diabetologia (2024)
In individuals with type 2 diabetes, treatment with SGLT2i was associated with better preservation of renal function compared with GLP-1RA, as evidenced by slower decline in eGFR. These findings reinforce SGLT2i as preferred agents for renal protection in this patient population.